相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience
Kamal Chamoun et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy
Simona Soverini et al.
MOLECULAR CANCER (2018)
Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy
Massimiliano Bonifacio et al.
LEUKEMIA RESEARCH (2018)
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
Andreas Hochhaus et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Journey of Generic Imatinib: A Case Study in Oncology Drug Pricing
Christopher T. Chen et al.
JOURNAL OF ONCOLOGY PRACTICE (2017)
Outcome of Frontline Treatment with Generic Imatinib In Adult Patients with Chronic Myeloid Leukemia in Algerian Population: A Multicenter Study
B. Entasoltan et al.
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES (2017)
Generic Imatinib Therapy Among Jordanians: An Observational Assessment of Efficacy and Safety in Routine Clinical Practice
Abdalla Awidi et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec
Ahmet Emre Eskazan et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
The Efficacy of Generic Imatinib as First- and Second-line Therapy: 3-Year Follow-up of Patients With Chronic Myeloid Leukemia
Erna Islamagic et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
Comparison of Branded and Generic Imatinib Plasma Concentrations in Patients With Chronic Myelogenous Leukemia: Unicentric Study
Alen Ostojic et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2016)
Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population
Hannah Bower et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Variations in Patients' Perceptions and Use of Generic Drugs: Results of a National Survey
Aaron S. Kesselheim et al.
JOURNAL OF GENERAL INTERNAL MEDICINE (2016)
Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States
William V. Padula et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Generic oncology drugs: are they all safe?
Y. Tony Yang et al.
LANCET ONCOLOGY (2016)
Chronic myeloid leukemia patients call for quality and consistency when generics are introduced to treat their cancer
J. Geissler et al.
LEUKEMIA (2016)
A Multi-centric Bioequivalence Trial in Ph plus Chronic Myeloid Leukemia Patients to Assess Bioequivalence and Safety Evaluation of Generic Imatinib Mesylate 400 mg Tablets
Rachna Arora et al.
CANCER RESEARCH AND TREATMENT (2016)
Prevalence and Predictors of Generic Drug Skepticism Among Physicians: Results of a National Survey
Aaron S. Kesselheim et al.
JAMA INTERNAL MEDICINE (2016)
Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States
William V. Padula et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU
Rena M. Conti et al.
ANNALS OF HEMATOLOGY (2015)
Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials
Koji Sasaki et al.
LANCET HAEMATOLOGY (2015)
Clinical efficacy of generic imatinib
Mario L. de Lemos et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2015)
First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate
Ahmet Emre Eskazan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia
Stacie B. Dusetzina et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia
Ahmet Emre Eskazan et al.
LEUKEMIA & LYMPHOMA (2014)
Deleterious effects of non-branded versions of imatinib used for the treatment of patients with chronic myeloid leukemia in chronic phase: a case series on an escalating issue impacting patient safety
Domingo Saavedra et al.
LEUKEMIA & LYMPHOMA (2014)
Prospective single-center study of chronic myeloid leukemia in chronic phase: switching from branded imatinib to a copy drug and back
Alaa Fadhil Alwan et al.
LEUKEMIA & LYMPHOMA (2014)
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
David M. Ross et al.
BLOOD (2013)
Failure of copy Imatib (CIPLA, India) to maintain hematologic and cytogenetic responses in chronic myeloid leukemia in chronic phase
Mervat Mattar
INTERNATIONAL JOURNAL OF HEMATOLOGY (2010)
Hematologic and Molecular Responses to Generic Imatinib in Patients With Chronic Myeloid Leukemia
Farnaz Razmkhah et al.
LABMEDICINE (2010)
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Francois-Xavier Mahon et al.
LANCET ONCOLOGY (2010)
Hematologic Relapse after 2 Years on a Non-Authorized Copy Version of Imatinib in a Patient with Chronic Myeloid Leukemia in Chronic Phase: A Case Report
Zoubir Chouffai
CASE REPORTS IN ONCOLOGY (2010)
Bioequivalence of Two Film-Coated Tablets of Imatinib Mesylate 400 mg: A Randomized, Open-Label, Single-Dose, Fasting, Two-Period, Two-Sequence Crossover Comparison in Healthy Male South American Volunteers
Susana Parrillo-Campiglia et al.
CLINICAL THERAPEUTICS (2009)
分享论文
